| Primary information |
|---|
| OV_ID | OV_359 |
| Virus Name | Adenovirus |
| Strain | AdLacZ |
| Virus type | DNA |
| Virus family | Adenoviridae |
| Modification in virus genome | E1/E3-deleted mutant |
| Virus alone | No |
| Virus in combination iwth drug/radiation | Virus in combination with temozolomide (TMZ) intraperitoneally at 50 mg/Kg for five consecutive days |
| Immune gene induction in virus genome | No |
| Source of cell line | NA |
| Origin of cell line | NA |
| Cell line | NA |
| Concentration of cell line | 0 |
| In-vitro toxicity | NA |
| Assay | NA |
| In-vitro virus concentration | NA |
| In-vitro result | NA |
| Model organism | Athymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5 × 10ⶠcells ) |
| In-vivo virus concentration | 1 × 10⹠pfu (every 3 days for at total 4 treatments) |
| In-vivo toxicity | NA |
| In-vivo result | 30% smaller tumor size compared to the negative control virus AdLacZ |
| Mode of delivery | Intratumorally |
| Pathway induction | JNK activation induces autophagy |
| Immunogenic effect | NA |
| Clinical trial | NA |
| PMID | 26561948 |